Chief Accounting Officer
Board Member
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
The company reported in an 8-K filed January 12, 2026 that Jason Cavalier was terminated as Chief Financial Officer and Treasurer, effective January 9, 2026. The proxy statement of the company reports total compensation of $782,861 for Jason Cavalier in fiscal 2021, including a base salary of $123,077. Jason Cavalier has spoken on 1 earnings call across 1 company, most recently on November 9, 2021.
“On January 9, 2026, in connection with the Plan described in Item 2.05, the employment of Dr. Maria Palasis, the Company's Chief Executive Officer, President and Chairman of the Board, and of Mr. Jason Cavalier, the Company's Chief Financial Officer and Treasurer, was terminated.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
Organization not stated
Chief Accounting Officer
SEC 8-K
2021-09-12–present
Organization not stated
SEC 8-K
2021-09-12–present
Organization not stated
Board Member
Proxy statement
2021-01-01–present
Organization not stated
CFO
Proxy statement
Start not stated–2026-01-09
Organization not stated
CFO
Proxy statement
Start not stated–2026-01-09
Recorded roles and call appearances connecting this person to public companies.
Company
Chief Accounting Officer, Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | — | Chief Financial Officer | $123,077 | $782,861 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
Lyra Therapeutics, Inc. Q3 FY2021 Earnings Call
